Impact of opioid rescue medication for breakthrough pain on the efficacy and tolerability of long-acting opioids in patients with chronic non-malignant pain

British Journal of Anaesthesia

Volumn 103, Issue 4, 2009, Pages 576-585

  Devulder, J ^a   Jacobs, A ^b   Richarz, U ^c   Wiggett, H ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Dianthus Medical Limited   (United Kingdom)

^c Cilag AG   (Switzerland)

Author keywords

Analgesics opioid; Pain, chronic; Pharmacology, analgesics opioid

Indexed keywords

BUPRENORPHINE; CODEINE; DIHYDROCODEINE; FENTANYL; LONG ACTING DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; SHORT ACTING DRUG; TILIDINE; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ANALGESIA; BREAKTHROUGH PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EMBASE; HUMAN; LONG TERM CARE; MEDLINE; NAUSEA; PAIN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; CHEMISTRY; CHRONIC DISEASE; DRUG INTERACTION; TREATMENT OUTCOME;

ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; DRUG INTERACTIONS; HUMANS; PAIN; TREATMENT OUTCOME;

EID: 70350448507     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aep253     Document Type: Article

References (75)

1. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001; 322: 1154-1158
2. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naiv̈e patients with chronic low back pain. Spine 2005; 30: 2484-2490
3. Arkinstall W, Sandler A, Goughnour B, et al. Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. Pain 1995; 62: 169-178
4. Babul N, Noveck R, Chipman H, et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J Pain Symptom Manage 2004; 28: 59-71
5. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943-1953
6. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 1: Assessment. Pharm Ther 2005; 30: 296-301 (Pubitemid 40734311)
7. Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: Management. Pharm Ther 2005; 30: 354-361 (Pubitemid 40885216)
8. Bennett DS, Simon S, Brennan M, Shoemaker SA. Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics. J Opioid Manag 2007; 3: 101-106
9. Berliner M, Schwalen S, Seidel W, Häntzschel H. Fentanyl-TTS in the treatment of pain caused by rheumatoid arthritis. Akt Rheumatol 2002; 27: 230-235
10. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in postherpetic neuralgia: a randomized, double-blind, placebocontrolled trial. Pain 2003; 104: 323-331
11. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999; 26: 862-869
12. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebocontrolled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002; 23: 278-291
13. Caraceni A, Martini C, Zecca E, et al. Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004; 18: 177-183
14. Casals M, Samper D. Effectiveness, tolerability and quality of life in the management of chronic pain unrelated to cancer with sustained-release tramadol administered in a single daily dose. Rev Soc Esp Dolor 2004; 11: 129-140
15. Chelminski PR, Ives TJ, Felix KM, et al. A primary care, multidisciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res 2005; 5: 3
16. Chen J, Kou BL, Yuan YL, Gao T. Advantage of controlled-release tramadol in treatment of chronic musculoskeletal pain. Chin J Clin Rehabil 2005; 9: 222-224
17. Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 2004; 20: 1419-1428
18. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998; 16: 220-229
19. Flöter VT, Brunnmüller U. Tilidine/naloxone slow release for the long-term treatment of chronic pain patients. Fortschritte der Medizin 2002; 120: 29-35
20. Fredheim OM, Kaasa S, Dale O, et al. Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study. Palliat Med 2006; 20: 35-41
21. Gaertner J, Frank M, Bosse B, et al. Controlled release oxycodone for the treatment of chronic pain. Med Welt 2003; 54: 310-314
22. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60: 927-934
23. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998; 15: 185-194
24. Højsted J, Nielsen PR, Eriksen J, et al. Breakthrough pain in opioid-treated chronic non-malignant pain patients referred to a multidisciplinary pain centre: a preliminary study. Acta Anaesthesiol Scand 2006; 50: 1290-1296
25. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
26. Jage J. Opioid tolerance and dependence-do they matter? Eur J Pain 2005; 9: 157-162
27. Jamison RN, Raymond SA, Slawsby EA, et al. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine 1998; 23: 2591-2600
28. Kahan M, Srivastava A, Wilson L, et al. Opioids for managing chronic non-malignant pain: safe and effective prescribing. Can Fam Physician 2006; 52: 1091-1096
29. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-380
30. Kosinski MR, Schein JR, Vallow SM, et al. An observational study of health-related quality of life and pain outcomes in chronic low back pain patients treated with fentanyl transdermal system. Curr Med Res Opin 2005; 21: 849-862
31. Langford R, McKenna F, Ratcliffe S, et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1829-1837
32. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005; 12: 379-384
33. Malonne H, Coffiner M, Fontaine D, et al. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J Clin Pharm Ther 2005; 30: 113-120
34. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain 2005; 21: 524-535
35. Marshall DA, Strauss ME, Pericak D, et al. Economic evaluation of controlled-release oxycodone vs. oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. Am J Manag Care 2006; 12: 205-214
36. McCarberg BH. The treatment of breakthrough pain. Pain Med 2007; 8: S8-13
37. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 2005; 12: 106-112
38. Menefee LA, Frank ED, Crerand C, et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med 2004; 5: 42-49
39. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of longterm efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2001; 2: 197-204
40. Mongin G, Yakusevich V, Köpe A, et al. Efficacy and safety assessment of a novel once-daily tablet formulation of tramadol: a randomised, controlled study versus twice-daily tramadol in patients with osteoarthritis of the knee. Clin Drug Investig 2004; 24: 545-558
41. Moulin DE, Iezzi A, Amireh R, et al. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996; 347: 143-147
42. Muriel C, Failde I, Micó JA, et al. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther 2005; 27: 451-462
43. Mystakidou K, Parpa E, Tsilika E, et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 2003; 4: 298-306
44. Nicholson B, Ross E, Weil A, et al. Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. Curr Med Res Opin 2006; 22: 539-550
45. Niemann T, Madsen LG, Larsen S, Thorsgaard N. Opioid treatment of painful chronic pancreatitis. Int J Pancreatol 2000; 27: 235-240
46. Otis J, Rothman M. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin 2006; 22: 1493-1501
47. Pavelka K, Le Loet X, Bjorneboe O, et al. Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: an open-label study to assess pain control. Curr Med Res Opin 2004; 20: 1967-1977
48. Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000; 27: 764-771
49. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006; 7: 583-591
50. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-281
51. Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007; 23: 223-233 (Pubitemid 46191684)
52. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999; 81: 129-134
53. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 2000; 14: 111-119
54. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology 2002; 59: 1015-1021
55. Ringe JD, Faber H, Bock O, et al. Transdermal fentanyl for the treatment of back pain caused by vertebral osteoporosis. Rheumatol Int 2002; 22: 199-203
56. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000; 160: 853-860
57. Russell A, Watson CP, Clark AJ, et al. Evaluation of dosing guidelines for use of controlled-release codeine in chronic noncancer pain. Pain Res Manag 2003; 8: 143-148
58. Schofferman J. Long-term opioid analgesic therapy for severe refractory lumbar spine pain. Clin J Pain 1999; 15: 136-140
59. Simon S, Bennett DS, Rauck R, et al. Breakthrough pain in opioidtreated patients with neuropathic pain. J Opioid Manag 2006; 2: 347-352
60. Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 588-601 (Pubitemid 47016640)
61. Simpson RK, Jr, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl as treatment for chronic low back pain. J Pain Symptom Manage 1997; 14: 218-224
62. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007; 5: 327-334
63. Sloan P, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006; 3: 489-497
64. Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005; 9: 195-206
65. Tassain V, Attal N, Fletcher D, et al. Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 2003; 104: 389-400
66. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007; 8: 281-288
67. Theodoridis T, Waap I, Schwalen S, Krämer J. Fentanyl-TTS in the treatment of pain caused by arthrosis. Z Orthop Ihre Grenzgeb 2003; 141: 217-222
68. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21: 1559-1573
69. Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage 2007; 33: 67-77
70. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-1841
71. Watson CP, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-78
72. Wilder-Smith CH, Hill L, Spargo K, Kalla A. Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects. Pain 2001; 91: 23-31
73. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliat Med 2001; 15: 243-246
74. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 2006; CD004311
75. Zimmermann M, Waap I. Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS. MMW Fortschr Med 2005; 147: 33-40